Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Birociclib plus fulvestrant versus placebo plus fulvestrant in endocrine-pretreated HR-positive/HER2-negative advanced breast cancer
CTR20212307Phase 3Completed
- Sponsor
- Jilin Sihuan Pharmaceutical
- Start
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of birociclib in breast cancer, sponsored by Jilin Sihuan Pharmaceutical. Started Dec 2021; status: completed.
02
Drugs
birociclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20212307.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212307.